Welcome to our dedicated page for SORRENTO THERAPEUTICS news (Ticker: SRNE), a resource for investors and traders seeking the latest updates and insights on SORRENTO THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SORRENTO THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SORRENTO THERAPEUTICS's position in the market.
Sorrento Therapeutics (Nasdaq: SRNE) has initiated enrollment in its Phase 2 placebo-controlled study of COVI-MSC for COVID-19-induced acute respiratory distress in Brazil, with the first patient enrolled. A second site is set to begin enrollment soon, with additional sites planned in the coming month. The study aims to evaluate the efficacy and safety of three infusions of COVI-MSC in 100 subjects. Sorrento is also launching two more Phase 2 studies in the U.S. and Brazil, focusing on safety and efficacy for different patient groups.
Sorrento Therapeutics has announced an exclusive license agreement with Texas A&M University System for the development of main protease (MPro) inhibitors targeting SARS-CoV-2. The lead compound, MPI8, demonstrated superior antiviral efficacy in in vitro tests, showing up to ten-fold higher potency compared to a competing antiviral, EIDD-2801, against SARS-CoV-2 variants. Further preclinical studies are planned, and results will soon be shared in a pre-print publication, emphasizing Sorrento's commitment to combating COVID-19.
Sorrento Therapeutics (Nasdaq: SRNE) announced promising preclinical results for its mRNA vaccine, STI-mRNA, delivered via the MuVaxx Lymphatic Drug Delivery Device. At one-tenth the dose of the reference standard, STI-mRNA showed a 400% increase in cellular immunity while maintaining similar humoral immunity. The device aims to improve immune response by targeting skin and lymph nodes. These findings support the advancement of the MultiValent STI-mRNA vaccine candidate into IND-enabling studies. The vaccine hopes to offer improved durability against emerging SARS-CoV-2 variants.
Sorrento Therapeutics (Nasdaq: SRNE) announced an exclusive option agreement with The Texas A&M University System for potent main protease (MPro) inhibitors targeting SARS-CoV-2. The lead compound, MPI8, shows strong antiviral activity against various COVID-19 variants. Sorrento aims to develop these inhibitors for oral administration and use in antiviral therapies to effectively combat current and emerging coronavirus infections. This agreement enhances Sorrento's existing COVID-19 therapeutic portfolio.
Sorrento Therapeutics (SRNE) announced a patient case report showcasing the effectiveness of its Sofusa Lymphatic Delivery System for administering Enbrel in a rheumatoid arthritis patient unresponsive to traditional subcutaneous injections. After 12 weeks, the patient's disease activity, measured by DAS28-ESR, decreased by 34.1%, demonstrating a shift from moderate to low disease activity. The method offers potential benefits by targeting lymphatic delivery, which may enhance therapeutic responses and reduce dosing requirements.
Sorrento Therapeutics (Nasdaq: SRNE) announced promising preclinical results for its COVID-19 vaccine candidate, DYAI-100. The vaccine demonstrated strong B-cell immunity against the original SARS-CoV-2 strain and key variants, including Alpha, Beta, Gamma, and Delta. Neutralization tests showed potent activity in vaccinated mice. Sorrento is collaborating with Dyadic International to prepare for human trials. DYAI-100 aims to be a universal vaccine and booster, enhancing protection against emerging variants. The company is advancing IND-enabling studies for future regulatory submissions.
Scilex Holding Company, a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE), announced the addition of ZTlido® (lidocaine topical system) 1.8% to multiple formularies, expanding coverage for up to 33 million lives starting September 1, 2021. This expansion allows for better access to ZTlido, indicated for pain relief associated with post-herpetic neuralgia (PHN). Currently, it covers about 65% of lives nationally, with reduced prior authorization requirements. ZTlido’s proprietary ZTech technology offers superior bioavailability compared to conventional lidocaine patches.
Sorrento Therapeutics has secured exclusive rights in various regions, including North and South America and Europe, to use Dyadic’s C1 technology for developing vaccines and therapeutics against coronaviruses, notably DYAI-100, its lead COVID-19 vaccine candidate. The agreement includes a $10 million upfront payment, reimbursement of R&D expenses, and future milestone payments. DYAI-100 has shown promise in inducing neutralization against SARS-CoV-2 and variants. This collaboration aims to enhance global vaccine production and accessibility.
Sorrento Therapeutics (Nasdaq: SRNE) announced a new presentation detailing its proprietary mRNA vaccine development program for COVID-19 on its website. Key highlights include:
- A MultiValent COVID Vaccine candidate targeting early variants and engineered to enhance immune response.
- Thermostable mRNA formulation allowing for transport without freezing.
- Lyophilized dose forms for improved delivery to underserved populations.
- A micro-epidermal infusion patch that achieves effective immune response with lower dosing.
For more information, visit Sorrento's corporate website.
Sorrento Therapeutics (Nasdaq: SRNE) announced a publication by the American Chemical Society regarding the effectiveness of Salicyn-30, a derivative screened from a salicylanilide library, in reducing SARS-CoV-2 replication in a rodent model. The study found that Salicyn-30 may lower viral loads and mitigate severe weight loss during COVID-19 infections. Given its promising pharmacokinetic profile and potential efficacy against emerging variants, Salicyn-30 is positioned as a significant therapeutic candidate for COVID-19.
FAQ
What is the current stock price of SORRENTO THERAPEUTICS (SRNE)?
What is the market cap of SORRENTO THERAPEUTICS (SRNE)?
